▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / CELZ

CELZ — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1187953 ·
Last close
$2.34
Market Cap
$8.65M
52W High
$2.48
52W Low
$1.75
ADV30
57,797
Next earnings
—
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 0 -1,459,153 -1,405,077 6,440,577 5,723,176 307,649
Dec 2025 3,000 2,006 -1,945,782 -1,887,674 7,809,525 7,208,126 284,880
Sep 2025 0 0 -1,273,034 -1,235,934 5,853,003 5,375,511 261,353
Jun 2025 0 0 -1,263,520 -1,233,303 7,105,228 6,544,120 277,644

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,856,445
Investing CF
$-50,500
Financing CF
$7,174,669
CapEx
—
Dividends Paid
—
Buybacks
$-10,000
EPS Diluted TTM
$-2.54
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-70,586,921
Inventory
$0
Receivables
$52,084
ST Investments
$0
EBIT TTM
$-6,142,814
Pretax Income TTM
$-5,995,008
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,000
EBITDA
$-5,819,884
Free Cash Flow
$-3,636,678
Enterprise Value
$3,024,414
Total Cash
$5,848,176
Total Debt
$14,194
Shares Out
3,696,668
Trailing EPS
$-2.07
Book Value
$1.65
ROE
-81.2%
ROA
-50.2%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 6,000 -6,142,814 -5,995,008 7,809,525 284,880 — -5,856,445
Dec 2024 11,000 -5,743,861 -5,493,481 6,669,143 327,644 — -5,301,292
Dec 2023 9,000 -5,620,132 -5,286,574 10,715,190 371,394 — -8,027,885
Dec 2022 88,600 -10,244,372 -10,144,044 19,186,326 3,321,652 — -7,796,966
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.51

Peers — same industry

TickerNameMarket CapLastDaily %
PMCB PharmaCyte Biotech, Inc. $8.43M $0.79 —
LIMN Liminatus Pharma, Inc. $7.36M $0.16 —
BCDA BioCardia, Inc. $10.36M $0.91 —
BCLI BRAINSTORM CELL THERAPEUTICS INC. $6.95M $0.63 —
CUBT Curative Biotechnology Inc $11.49M $1.50 —

News headlines (Yahoo Finance, 1h cache)

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
2026-04-28 13:01 · Yahoo
Analysts Expect Breakeven For Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Before Long
2026-04-09 10:56 · Yahoo
Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
2026-02-10 14:00 · Yahoo
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
2026-01-13 14:15 · Yahoo
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
2026-01-06 14:15 · Yahoo
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
2025-12-17 14:15 · Yahoo
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
2025-12-02 14:15 · Yahoo
Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now
2025-11-05 14:55 · Yahoo
Market Sentiment Around Loss-Making Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ)
2025-10-31 10:39 · Yahoo
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
2025-10-30 13:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →